Osimertinib and Bevacizumab as Treatment for EGFR-mutant Lung Cancers
Status:
Active, not recruiting
Trial end date:
2022-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test the safety of combining the drugs osimertinib and
bevacizumab at different dose levels. The investigators want to find out what effects, good
and/or bad, taking osimertinib and bevacizumab has on the patient and lung cancer. This study
will try to find the best dose of osimertinib and bevacizumab given together that does not
cause significant side effects. Once the investigators determine that combining osimertinib
and bevacizumab is safe, they want to see if the combination is effective in treating lung
cancers with the EGFR mutation.